A previous clinical trial has shown that targeting IL-1β reduced cardiovascular events [97], and one recent cross-sectional study reported that IL-1β levels were reduced in an SCI cohort with an anti-inflammatory intervention [98], These studies suggest that treatments targeted at IL-1β may have efficacy in AD and SCI. This evidence concerns the gene IL1B and Alzheimer disease.